UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Annals of oncology, 2014-01, Vol.25 (1), p.32-40

2014

Volltextzugriff (PDF)

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Annals of oncology, 2019-04, Vol.30 (4), p.551-557

2019

Volltextzugriff (PDF)

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of oncology, 2023-10, Vol.34, p.S1292-S1292

2023

Volltextzugriff (PDF)

The generalizability of NCI-sponsored clinical trials accrual amongst women with gynecologic malignancies

Gynecologic oncology, 2016-06, Vol.141, p.14-15

2016

Volltextzugriff (PDF)

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Annals of oncology, 2018-10, Vol.29, p.viii334-viii334

2018

Volltextzugriff (PDF)

Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?

Annals of oncology, 2005-01, Vol.16 (1), p.16-22

2005

Volltextzugriff (PDF)

Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC)

Gynecologic oncology, 2014-06, Vol.133, p.104-104

2014

Volltextzugriff (PDF)

Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC)

Gynecologic oncology, 2015-04, Vol.137, p.44-44

2015

Volltextzugriff (PDF)

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii8-viii12

2017

Volltextzugriff (PDF)

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

Annals of oncology, 2024-09, Vol.35, p.S749-S749

2024

Volltextzugriff (PDF)

746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

Annals of oncology, 2023-10, Vol.34, p.S511-S511

2023

Volltextzugriff (PDF)

LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

Annals of oncology, 2023-10, Vol.34, p.S1285-S1285

2023

Volltextzugriff (PDF)

Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review

Gynecologic oncology, 2022-03, Vol.164 (3), p.473-480

2022

Volltextzugriff (PDF)

Clinical implications of using molecular diagnostics for ovarian cancers

Annals of oncology, 2013-12, Vol.24 Suppl 10 (Suppl 10), p.x22-x26

2013

Volltextzugriff (PDF)

Proteomics as a guiding tool for more effective personalized therapy

Annals of oncology, 2010-10, Vol.21 (suppl-7), p.vii205-vii210

2010

Volltextzugriff (PDF)

LBA60 - Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Annals of oncology, 2019-10, Vol.30, p.v897-v897

2019

Volltextzugriff (PDF)

Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Annals of oncology, 2019-10, Vol.30, p.v897

2019

Volltextzugriff (PDF)

A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)

Annals of oncology, 2016-10, Vol.27, p.vi296-vi296

2016

Volltextzugriff (PDF)

A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)

Annals of oncology, 2016-10, Vol.27, p.vi71-vi71

2016

Volltextzugriff (PDF)

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

BioTechniques, 2002-09, Vol.33 (3), p.664-670

2002

Volltextzugriff (PDF)

Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown

The Journal of biological chemistry, 1993-04, Vol.268 (11), p.7768-7772

1993

Volltextzugriff (PDF)

The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells

The Journal of biological chemistry, 1992-05, Vol.267 (13), p.9000-9004

1992

Volltextzugriff (PDF)

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

BioTechniques, 2002-09, Vol.33 (3), p.664-670

2002

Volltextzugriff (PDF)

Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets

International journal of gynecological cancer, 2005-11, Vol.15 (s3), p.266-273

2005

Volltextzugriff (PDF)

Ovarian cancer in the proteomics era

International journal of gynecological cancer, 2008-03, Vol.18 (Suppl 1), p.1-6

2008

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(19)
Humans
(17)
Female
(10)
Oncology
(10)
Biological And Medical Sciences
(7)
Biochemistry & Molecular Biology
(6)
Ovarian Cancer
(6)
Animals
(4)
Medical Sciences
(4)
Obstetrics & Gynecology
(4)
Ovarian Neoplasms - Diagnosis
(4)
Prognosis
(4)
Proteomics
(4)
Tumor Cells, Cultured
(4)
Antineoplastic Agents
(3)
Brca1 Protein - Genetics
(3)
Brca2 Protein - Genetics
(3)
Calcium - Metabolism
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

The generalizability of NCI-sponsored clinical trials accrual amongst women with gynecologic malignancies

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?

Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC)

Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC)

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review

Clinical implications of using molecular diagnostics for ovarian cancers

Proteomics as a guiding tool for more effective personalized therapy

LBA60 - Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)

A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown

The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets

Ovarian cancer in the proteomics era

Suchergebnisse filtern